CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States and throughout the world. It is also focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which include CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include CNCT19, BI-1206, CB-5339 and CID-103.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)